This is a phase I/II double blind, placebo-controlled, randomized trial of new non-nucelosidal reverse transcriptase inhibitor (HBY097) for patients with HIV infection compared to AZT (Zidovudine) and AZT plus HBY097.
Showing the most recent 10 out of 565 publications